![Bruce Turner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bruce Turner
Corporate Officer/Principal presso IMMUNOME, INC.
Patrimonio netto: 631 962 $ in data 31/05/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Clay Siegall | M | 63 |
MorphImmune, Inc.
![]() MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | 1 anni |
Max Rosett | M | 34 |
MorphImmune, Inc.
![]() MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | 2 anni |
Isaac Barchas | M | 56 | 1 anni | |
Todd Wider | M | - |
Xanadu Bio Inc.
| - |
Philip Wagenheim | M | 53 | 7 anni | |
Sandra Stoneman | F | 51 | 4 anni | |
Matthew Robinson | M | 55 | 8 anni | |
Andrew Ellis | M | 41 |
Boxer Capital LLC
![]() Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | 6 anni |
Julie Hambleton | M | 66 |
Gennao Bio, Inc.
![]() Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 3 anni |
Jack Higgins | M | 45 |
MorphImmune, Inc.
![]() MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | 2 anni |
Christopher M. Duke | M | 52 |
Gennao Bio, Inc.
![]() Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 3 anni |
Carol Schafer | F | 60 | - | |
Kinney Horn | M | 49 | - | |
Sam Gerson | M | - |
Boxer Capital LLC
![]() Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | 6 anni |
Todd Wider | M | 59 |
Xanadu Bio Inc.
| - |
Siddarth Subramony | M | 37 |
Boxer Capital LLC
![]() Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | 6 anni |
Bradley Campbell | M | 48 |
Gennao Bio, Inc.
![]() Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 2 anni |
James Boylan | M | 57 | 1 anni | |
James Avery | M | 59 |
Boxer Capital LLC
![]() Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | 5 anni |
Gary Sender | M | 62 |
Gennao Bio, Inc.
![]() Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 3 anni |
Craig David Gordon | M | - |
Gennao Bio, Inc.
![]() Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | - |
Peter Thompson | M | 64 |
Gennao Bio, Inc.
![]() Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 2 anni |
Jean-Jacques Bienaimé | M | 70 | 1 anni | |
Bob Lechleider | M | 63 | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Stephen P. Squinto | M | 67 |
Gennao Bio, Inc.
![]() Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 3 anni |
Purnanand Sarma | M | 59 | 4 anni | |
Corleen Roche | F | 58 | 3 anni | |
Rapp Rapoport | M | 56 | 8 anni | |
John LaMattina | M | 74 | 6 anni | |
Richard Baron | M | 68 | 3 anni | |
Michael Lefenfeld | M | 43 | 6 anni | |
Dennis Giesing | M | - | 2 anni | |
Philip Roberts | M | - | 1 anni | |
Dayton McMillan | M | - |
Boxer Capital LLC
![]() Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | 1 anni |
Robert Lapetina | M | 49 | 3 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 35 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Bruce Turner
- Contatti personali